Waters Corporation WAT
433.54
3.24
0.75%
as of 25 Sep
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Waters Corporation (WAT) Revenue growth
Waters Corporation's revenue growth over the twelve months to 30 June 2026 was 52.5%, up 45.5 percentage points from fiscal 2025 (6.99%). Over the past ten years it has ranged from −1.71% (fiscal 2020) to 17.8% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 7.69% and above the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 6.99% | 6.92 |
| FY2024 | 0.07% | 0.59 |
| FY2023 | −0.52% | (7.20) |
| FY2022 | 6.68% | (11.10) |
| FY2021 | 17.8% | 19.49 |
| FY2020 | −1.71% | (1.16) |
| FY2019 | −0.55% | (5.35) |
| FY2018 | 4.80% | (1.74) |
| FY2017 | 6.54% | 0.42 |
| FY2016 | 6.12% | 3.46 |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 113.4% | 21.97 |
| Mar 2026 | 91.4% | 84.55 |
| Dec 2025 | 6.84% | (1.21) |
| Sep 2025 | 8.05% | (0.77) |
| 42 more quarters | Free account |
Against its own ten years
Low −1.71%
High 17.8%
Ten-year median
4.80%
Current reading's percentile
91
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| WAT Waters Corporation | 52.5% |
| GH Guardant Health, Inc. compare | 42.7% |
| NTRA Natera, Inc. compare | 37.8% |
| IDXX IDEXX Laboratories, Inc. compare | 12.8% |
| DGX Quest Diagnostics Incorporated compare | 9.87% |
| A Agilent Technologies, Inc. compare | 8.60% |
| IQV IQVIA Holdings Inc. compare | 8.17% |
| MTD Mettler-Toledo International, Inc. compare | 6.91% |
| ILMN Illumina, Inc. compare | 4.88% |
| Diagnostics & Research industry median | 7.69% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on WAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement